• Open Access

Injectable cardiac tissue engineering for the treatment of myocardial infarction

Authors

  • Haibin Wang,

    1. Department of Tissue Engineering, Institute of Basic Medical Sciences and Tissue Engineering Research Center, Academy of Military Medical Sciences, Beijing, P.R. China
    Search for more papers by this author
    • #

      The first two authors contributed equally to this work.

  • Jin Zhou,

    1. Department of Tissue Engineering, Institute of Basic Medical Sciences and Tissue Engineering Research Center, Academy of Military Medical Sciences, Beijing, P.R. China
    Search for more papers by this author
    • #

      The first two authors contributed equally to this work.

  • Zhiqiang Liu,

    1. Department of Tissue Engineering, Institute of Basic Medical Sciences and Tissue Engineering Research Center, Academy of Military Medical Sciences, Beijing, P.R. China
    Search for more papers by this author
  • Changyong Wang

    Corresponding author
    1. Department of Tissue Engineering, Institute of Basic Medical Sciences and Tissue Engineering Research Center, Academy of Military Medical Sciences, Beijing, P.R. China
    Search for more papers by this author

Correspondence to: Changyong WANG, M.D., Ph.D.,
Department of Tissue Engineering, Institute of Basic Medical Sciences and Tissue Engineering Research Center, Academy of Military Medical Sciences, 27 Taiping Rd, Beijing 100850, P.R. China.
Tel.: 8610-66931592
Fax: 8610-68166874
E-mail: wcy2000@yahoo.com

Abstract

  • • Introduction
  • • Seeding cell sources
  • • Embryonic stem cells
  • • Induced pluripotent stem cells
  • • Adult stem cells
    • - Skeletal myoblasts (SkM)
    • - Bone marrow-derived stem cells
    • - Cardiac stem cells
    • - Other adult stem cells
  • • Biomaterials in the injectable cardiac tissue engineering
  • • Fibrin
  • • Alginate
  • • Matrigel
  • • Collagen
  • • Chitosan
  • • Other biomaterials
  • • Clinical applications
  • • Future perspectives

Heart disease is a leading cause of morbidity and mortality worldwide. Myocardial infarction leads to permanent loss of cardiac tissue and ultimately heart failure. However, current therapies could only stall the progression of the disease. Thus, new therapies are needed to regenerate damaged hearts to overcome poor prognosis of patients with heart failure. The shortage of heart donors is also a factor for innovating new therapies. Although the cardiac performance by cell-based therapy has improved, unsatisfactory cell retention and transplant survival still plague this technique. Because biomaterials can improve the cell retention, survival and differentiation, cardiac tissue engineering is now being explored as an approach to support cell-based therapies and enhance their efficacy for cardiac disease. In the last decade, cardiac tissue engineering has made considerable progress. Among different kinds of approaches in the cardiac tissue engineering, the approach of injectable cardiac tissue engineering is more minimally invasive than that of in vitro engineered tissue or epicardial patch implantation. It is therefore clinically appealing. In this review, we strive to describe the major progress in the flied of injectable cardiac tissue engineering, including seeding cell sources, biomaterials and novel findings in preclinical studies and clinical applications. The remaining problems will also be discussed.

Ancillary